Alnylam Pharmaceuticals, Inc. (ALNY) Shares Sold by Sphera Funds Management LTD.

Sphera Funds Management LTD. reduced its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 79.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,000 shares of the biopharmaceutical company’s stock after selling 155,232 shares during the quarter. Sphera Funds Management LTD.’s holdings in Alnylam Pharmaceuticals were worth $3,501,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. BTG Pactual Global Asset Management Ltd grew its stake in Alnylam Pharmaceuticals by 17.3% during the 2nd quarter. BTG Pactual Global Asset Management Ltd now owns 4,410 shares of the biopharmaceutical company’s stock worth $434,000 after buying an additional 652 shares during the last quarter. Skandinaviska Enskilda Banken AB publ grew its stake in Alnylam Pharmaceuticals by 7.1% during the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 12,070 shares of the biopharmaceutical company’s stock worth $1,056,000 after buying an additional 800 shares during the last quarter. Toronto Dominion Bank grew its stake in Alnylam Pharmaceuticals by 9.7% during the 3rd quarter. Toronto Dominion Bank now owns 9,827 shares of the biopharmaceutical company’s stock worth $860,000 after buying an additional 869 shares during the last quarter. Mutual of America Capital Management LLC grew its stake in Alnylam Pharmaceuticals by 98.5% during the 2nd quarter. Mutual of America Capital Management LLC now owns 1,935 shares of the biopharmaceutical company’s stock worth $191,000 after buying an additional 960 shares during the last quarter. Finally, Panagora Asset Management Inc. grew its stake in Alnylam Pharmaceuticals by 31.4% during the 3rd quarter. Panagora Asset Management Inc. now owns 4,094 shares of the biopharmaceutical company’s stock worth $358,000 after buying an additional 979 shares during the last quarter. Hedge funds and other institutional investors own 88.46% of the company’s stock.

Shares of ALNY stock opened at $74.38 on Friday. The company has a quick ratio of 10.96, a current ratio of 11.05 and a debt-to-equity ratio of 0.02. Alnylam Pharmaceuticals, Inc. has a 1 year low of $63.57 and a 1 year high of $153.99. The firm has a market cap of $8.06 billion, a price-to-earnings ratio of -13.72 and a beta of 2.54.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($2.43) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.02) by ($0.41). Alnylam Pharmaceuticals had a negative net margin of 754.13% and a negative return on equity of 43.07%. The firm had revenue of $2.07 million during the quarter, compared to analyst estimates of $22.66 million. During the same quarter last year, the company earned ($1.34) EPS. The company’s quarterly revenue was down 87.9% compared to the same quarter last year. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -7.75 EPS for the current year.

A number of brokerages recently commented on ALNY. BMO Capital Markets lowered their price objective on Alnylam Pharmaceuticals from $127.00 to $125.00 and set an “outperform” rating for the company in a research note on Monday, August 13th. Cantor Fitzgerald restated a “buy” rating and set a $135.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday. JMP Securities set a $198.00 price objective on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 28th. Cowen lowered their price objective on Alnylam Pharmaceuticals from $157.00 to $147.00 and set an “outperform” rating for the company in a research note on Monday, August 13th. Finally, Goldman Sachs Group downgraded Alnylam Pharmaceuticals from a “conviction-buy” rating to a “buy” rating in a research note on Monday, August 13th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $138.44.

ILLEGAL ACTIVITY NOTICE: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2018/12/08/alnylam-pharmaceuticals-inc-alny-shares-sold-by-sphera-funds-management-ltd.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.

Recommended Story: What are the components of an earnings report?

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply